Skip to main content

Companies researching Skyrizi (Risankizumab)

Skyrizi (risankizumab) is a humanized monoclonal antibody that inhibits interleukin‑23A and is jointly developed by Boehringer Ingelheim and AbbVie for treating plaque psoriasis.

List of companies that research Skyrizi (Risankizumab)

This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →

CompanyCountryIndustryEmployeesRevenueTechnologies

United States

Pharmaceutical Manufacturing

62k

$26B

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

285

$25M

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

501

$100M

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

201

$12M

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

343

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

1k

$6.4M

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

1k

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

94

Skyrizi (Risankizumab)

United States

Hospitals and Health Care

1k

$18M

Skyrizi (Risankizumab)

Showing top companies out of 17 that research Skyrizi (Risankizumab). Get the full list on TheirStack.

Frequently asked questions